Tardive Dyskinesia
A condition affecting the nervous system, often caused by long-term use of some psychiatric drugs.
Tardive dyskinesia is caused by long-term use of neuroleptic drugs, which are used to treat psychiatric conditions.
Tardive dyskinesia causes repetitive, involuntary movements, such as grimacing and eye blinking.
Stopping or tapering drugs that may be contributing to involuntary repetitive movements can help. In rare cases, botulinum toxin, deep brain stimulation, or medications can help.
Cluster Number:
Wiki Number: PW216
Diagnosis: Tardive Dyskinesia
US Patients: 30% of those taking antipsychotic medicines
World Patients:
Sex Ratio: M;F+
Age Onset: elderly
Brain Area:
Symptoms: involuntary, repetitive body movements: rapid-jerking or slow-writhing; grimacing, smacking lips, sticking out tongue, eye-blinking
Progression: walking is difficult or impossible due to excess leg movement
Causes: reactions to narcoleptic drugs; reactions to long-term-use of dopamine-receptor-blocking medications; antipsychotics
Medications: supersensitivity to dopamine becomes in the nigrostriatal pathway;discontinuing the narcoleptics helps; valbenazing, etc.
Therapies: No therapies listed; newer antipsychotic drugs cause less dyskinesia than the first generation of antipsychotic drugs did.
Youtube Video: Meet Jeff, Living with Tardive Dyskinesia
Amazon or Library Book:
Ultimate Medical Guide to Tardive Dyskinesia
Click the book to link or order from Amazon.
4 CURRENT ARTICLES
FROM PUBMED
The world-wide medical research
reports chosen for each diagnosis
Clicking each title opens the
PubMed article’s summary-abstract.
- Effects of Acute Haloperidol Treatment on Dopaminergic Markers, GAD67, and A2A Receptors in Rats with High and Low VCMsby Getulio Nicola Bressan on November 14, 2024
Vacuous chewing movements (VCM) have been utilized as an experimental model of orofacial dyskinesia (OD) in rodents to study the underlying molecular mechanisms related to tardive dyskinesia (TD). This study aimed to investigate if the acute treatment with haloperidol can alter components of the dopaminergic synapse or its modulators such as glutamic acid decarboxylase (GAD(67)) and adenosine 2A (A(2A)) receptor. Furthermore, to evaluate if changes in molecular markers are associated with the...
- Molecular and Behavioral Neuroprotective Effects of Clavulanic Acid and Crocin in Haloperidol-Induced Tardive Dyskinesia in Ratsby Parisa Shoae-Hagh on November 9, 2024
Clavulanic acid (ClvA), a beta-lactamase inhibitor, is being explored for its significant neuroprotective potential. The effects of ClvA were assessed both individually and in combination with crocin (Cr), an antioxidant derived from saffron, in the context of tardive dyskinesia (TD). In rat haloperidol (Hp)-induced-TD (1 mg/kg, i.p. 21 days), the effects of ClvA (50, 100, 150 mg/kg) and Cr (10, 20, 40 mg/kg) were assessed via vacuous chewing movements (VCM) and tongue protrusion (TP). Striatal...
- Successful Electroconvulsive Therapy for Tardive Dyskinesia and Tardive Dystonia Refractory to Valbenazine Treatment: A Case Report and Narrative Literature Reviewby Keisuke Irinaka on October 18, 2024
Tardive dyskinesia and dystonia are intractable extrapyramidal symptoms caused by the blockade of dopamine receptors by antipsychotic drugs. In addition to the reduction or discontinuation of the causative drug, valbenazine for tardive dyskinesia and botulinum toxin for tardive dystonia have been reported to be effective. However, their efficacy has not been fully demonstrated. In this study, we report the case of a female patient with bipolar disorder, valbenazine-resistant tardive dystonia,...
- A Multicenter, Open-Label Study to Evaluate the Long-term Safety and Efficacy of Adjunctive Brexpiprazole 2 mg Daily in Japanese Patients with Major Depressive Disorderby Masaki Kato on October 18, 2024
CONCLUSIONS: This is the first study to evaluate the safety profile of brexpiprazole 2 mg/day in Japanese patients with MDD, including older adults, which is similar to previous reports, with no new safety risks, and continued efficacy over 52 weeks.